CD86 and neoplasm: Studies have shown that NRTUA invasion can convert tumor-associated CD11c+ DCs into an immunostimulatory phenotype, thereby upregulating the expression of IL-12, major histocompatibility antigen I, and T-cell receptor costimulatory molecules CD80 and CD86 (Baird et al., 2013b).